Pharvaris

During Consortium of Independent Immunology Clinics (CIIC) Fall 2024 Conference, Joshua S. Jacobs, M.D. presented data from RAPIDe-2, the extension study of our lead candidate for #HereditaryAngioedema. We were able to connect with, and learn from, the #HAE community. View our posters here: https://shorturl.at/BYJQu #CIICFall2024

Seven posters from #Pharvaris studies will be presented at the American College of Allergy, Asthma and Immunology (ACAAI) #ACAAI24 Annual Meeting, taking place in Boston. Clinical and nonclinical updates on our development programs will be shared, including data highlighting the potential of #deucrictibant for the #prophylactic and #ondemand treatment of #HereditaryAngioedema (#HAE). Read the full press release here: https://bit.ly/3AfI3sr

Register now for our virtual investor event tomorrow, October 23, at 10 AM ET featuring Michael Manning, M.D. (Allergy, Asthma & Immunology, LTD, Scottsdale, Arizona) and Raffi Tachdjian, M.D., MPH (David Geffen School of Medicine at the University of California, Los Angeles), who will discuss the unmet medical need and current treatment landscape for #HereditaryAngioedema (HAE). Join us and register here: https://lnkd.in/g_tPPhwf

Are you a passionate and motivated #EnterpriseITArchitect looking for an opportunity to make a difference? #Pharvaris might be the company for you. We are expanding our team, looking for a European-based Enterprise IT Architect to help design, implement and maintain oversight of Pharvaris’ IT business systems, with a focus on the ERP system. Reporting to Stefan Abele, PH.D., our #ChiefTechnicalOperationsOfficer, this newly created #remote position will ensure our business systems centrally support our corporate ambitions as we aim to bring new, novel, oral alternatives to all people living with #HereditaryAngioedema (HAE). Visit https://lnkd.in/d3zgSkK for more information and to #apply.

I am eager to identify a APAC Regional Clinical Lead who has experience in clinical studies, monitoring and site engagement. The suitable candidate would have at least ten years industry experience, be self motivated and able to clearly and succinctly explain study design and deliverables. If this sounds like you please let me know.

I’m thrilled to announce that I have joined the #Pharvaris team as head of BD! I’m looking forward to progressing deucrictibant as an on-demand and prophylactic option for patients with #HAE as well as continuing to build the Pharvaris pipeline.

Enjoyed a vibrant and festive gala organized by the Swiss Chemical Society (SCS): the Swiss Chemistry and Science Night 2024 #SCSN24. It was again an honour to serve as master of ceremony together with Rachel Hevey and hand over the renowned SCS Awards to the 2024 Awardees, @https://lnkd.in/dhba-qFu https://lnkd.in/dz7RUb_h A big THANK YOU to David Spichiger and his fantastic team, Céline Wittwer and Sarah Schmitz for their limitless and enthusiastic creativity in making the Swiss Chemical Society (SCS) a beacon amongst national Chemical Societies. On stage with Prof. Christian Bochet, Rachel Hevey, Agnes Zoller, PhD, David Spichiger

On September 6th, I had the opportunity to present at the Bradykinin Symposium in Berlin the highly encouraging one-year interim results from the ONCE-AID study. In this investigator-initiated, open-label study conducted at the Amsterdam UMC with Principal Investigator Danny M. Cohn, four patients with angioedema due to acquired C1-inhibitor deficiency administered deucrictibant 40 mg extended-release (XR) tablet once daily. The potential of deucrictibant as long-term prophylaxis for this patient group was shown: three patients remained attack-free from the start of treatment and the fourth patient has been attack-free for over a year, following a single attack shortly after treatment initiation. Deucrictibant XR tablet was well tolerated, with no drug-related adverse events.

Pharvaris is saddened by the passing of Professor Marcus Maurer, a distinguished leader in the fields of dermatology, allergy, and hereditary angioedema (HAE) research and clinical practice. Prof. Maurer was pivotal in advancing knowledge and care of HAE, also contributing to numerous clinical programs for HAE therapies. His medical knowledge, scientific rigor, commitment to patient care, and proactive collaboration with his partners, including Pharvaris, will have lasting impacts on the advancement of care and of new treatment options for people living with HAE. We will miss Prof. Maurer dearly and are forever grateful for his contributions to the HAE community. We extend our sincerest condolences to his family, friends, colleagues, and patients.

We have been selected as a finalist for the Post IPO of the Year category of the European Lifestars Awards - Celebrating Life Science Leaders, recognizing the significance of our $300 million underwritten offering that closed last December. In addition, our CEO, Berndt Modig, is a finalist for the Public Company CEO of the Year category emphasizing his unwavering commitment to leading Pharvaris through the advancement of our #HereditaryAngioedema (#HAE) pipeline. Winners of each category will be announced on November 18. Learn more: https://lnkd.in/dNeDbkCx